CAMBRIDGE, Mass.–(BUSINESS WIRE)–C4 Therapeutics (C4T) today announced the appointment of Michael Kim,
Ph.D., as Vice President of Business Development. Dr. Kim comes to C4
Therapeutics from ARIAD Pharmaceuticals where he held responsibilities
for partnering activities around early and late stage programs in
addition to portfolio strategy and alliance management. He started his
business career as a strategy consultant with Leerink Swann and Company
and progressed to Corporate Strategy and Business Development roles of
increasing responsibility at Alkermes, Vertex Pharmaceuticals and FORUM
Pharmaceuticals. He received his post-doctoral training as an NIH NRSA
Fellow at Harvard Medical School and holds a Ph.D. in Biomedical
Engineering from the University of Rochester.
“We are incredibly pleased to have Michael join us,” said Andy Phillips,
C4T’s President and Chief Scientific Officer. “Michael’s combined
scientific and business background, coupled to his track record in
matching portfolio strategy with external opportunities, are a superb
match for C4T. We are all looking forward to the impact he will bring
during this next exciting phase of C4T’s growth.”
About C4 Therapeutics
C4 Therapeutics is pioneering a new class of drugs. C4’s technology
platform produces small molecule drugs that harness machinery already
present in cells to selectively target disease-relevant proteins for
degradation. Our approach has the potential to address a broad range of
diseases including cancer, infectious disease, and autoimmune disorders.
To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.